Physician profile
Michael Taylor
NPI 1831161280
$4,014.15
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,466 · 2020: $96.57 · 2021: $667 · 2022: $785.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $1,149.79 | 2019 | |
| Amgen INC. | $741.54 | 2019-2022 | |
| Abbvie INC. | $387.52 | 2021-2022 | |
| Astellas Pharma US INC | $292.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.00 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $214.99 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $143.61 | 2019 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $93.81 | 2021 | |
| Edwards Lifesciences Corporation | $90.45 | 2019 | |
| Novo Nordisk INC | $60.34 | 2019 | |
| Abbott Laboratories | $58.42 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.10 | 2022 | |
| Pfizer INC. | $38.18 | 2019 | |
| Glaxosmithkline, LLC. | $32.53 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $27.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.73 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.83 | 2019 | |
| Lilly USA, LLC | $23.94 | 2021 | |
| Almatica Pharma LLC | $23.40 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.18 | 2022 | |
| Genzyme Corporation | $17.81 | 2022 | |
| Mylan Specialty L.P. | $17.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2019 | |
| Endo Pharmaceuticals INC. | $13.77 | 2019 | |
| Medtronic USA, INC. | $13.15 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $12.05 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.04 | 2020 | |
| Allergan, INC. | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.